ADAPTIVE BIOTECHNOLOGIES COR's ticker is ADPT and the CUSIP is 00650F109. A total of 230 filers reported holding ADAPTIVE BIOTECHNOLOGIES COR in Q2 2021. The put-call ratio across all filers is 0.39 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2023 | $1,261,238 | +47819.4% | 187,964 | -36.9% | 0.00% | -100.0% |
Q1 2023 | $2,632 | -67.2% | 298,041 | -71.6% | 0.00% | -50.0% |
Q4 2022 | $8,013 | -99.9% | 1,048,869 | +32.5% | 0.00% | +33.3% |
Q3 2022 | $5,638,000 | +5.9% | 791,824 | +20.4% | 0.00% | 0.0% |
Q2 2022 | $5,322,000 | -35.0% | 657,833 | +11.5% | 0.00% | -25.0% |
Q1 2022 | $8,187,000 | +93.0% | 589,825 | +290.1% | 0.00% | +100.0% |
Q4 2021 | $4,242,000 | +170.7% | 151,185 | +227.9% | 0.00% | +100.0% |
Q3 2021 | $1,567,000 | +26.3% | 46,107 | +51.8% | 0.00% | 0.0% |
Q2 2021 | $1,241,000 | -38.9% | 30,372 | -39.8% | 0.00% | 0.0% |
Q1 2021 | $2,030,000 | -71.3% | 50,416 | -57.8% | 0.00% | -80.0% |
Q4 2020 | $7,071,000 | +1082.4% | 119,586 | +497.9% | 0.01% | +400.0% |
Q4 2019 | $598,000 | -88.7% | 20,000 | -88.3% | 0.00% | -87.5% |
Q3 2019 | $5,284,000 | -84.5% | 171,018 | -75.8% | 0.01% | -84.3% |
Q2 2019 | $34,171,000 | – | 707,467 | – | 0.05% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Blue Water Life Science Advisors, LP | 3,030,434 | $20,334,212 | 13.72% |
BERYLSON CAPITAL PARTNERS, LLC | 228,000 | $1,529,880 | 4.32% |
Eagle Health Investments LP | 1,214,860 | $8,151,711 | 1.52% |
Matrix Capital Management Company, LP | 11,572,590 | $77,652,079 | 0.90% |
Triatomic Management LP | 121,166 | $813,024 | 0.83% |
VIKING GLOBAL INVESTORS LP | 29,993,708 | $201,257,781 | 0.82% |
Aristotle Atlantic Partners, LLC | 3,104,961 | $20,834,288 | 0.78% |
Pier Capital, LLC | 737,589 | $4,949,222 | 0.71% |
ARK Investment Management | 10,453,752 | $70,144,675 | 0.46% |
Nikko Asset Management Americas, Inc. | 6,384,047 | $42,773,115 | 0.45% |